Lquin: Advanced Fluoroquinolone Therapy for Severe Bacterial Infections
| Product dosage: 250mg | |||
|---|---|---|---|
| Package (num) | Per pill | Price | Buy |
| 90 | $0.46 | $41.28 (0%) | 🛒 Add to cart |
| 120 | $0.42 | $55.04 $49.88 (9%) | 🛒 Add to cart |
| 180 | $0.37 | $82.56 $66.22 (20%) | 🛒 Add to cart |
| 270 | $0.27 | $123.84 $73.96 (40%) | 🛒 Add to cart |
| 360 | $0.25
Best per pill | $165.12 $89.44 (46%) | 🛒 Add to cart |
Lquin (levofloxacin) is a broad-spectrum fluoroquinolone antibiotic indicated for the treatment of adults with complicated and uncomplicated infections caused by susceptible strains of designated microorganisms. As a third-generation fluoroquinolone, it demonstrates enhanced gram-positive coverage while maintaining potent activity against gram-negative pathogens. Its optimized pharmacokinetic profile allows for once-daily dosing, supporting patient adherence and therapeutic efficacy. Clinicians rely on Lquin for its proven efficacy in respiratory, skin, and urinary tract infections where resistance or severity necessitates a potent antimicrobial approach.
Features
- Active ingredient: Levofloxacin 250mg, 500mg, or 750mg film-coated tablets
- Mechanism: Inhibition of bacterial DNA gyrase and topoisomerase IV
- Spectrum: Broad activity against gram-positive, gram-negative, and atypical pathogens
- Bioavailability: Approximately 99%, unaffected by food
- Half-life: 6–8 hours, permitting once-daily administration
- Excretion: Primarily renal, requiring dosage adjustment in impaired renal function
Benefits
- Rapid bactericidal action reduces microbial load and shortens infection duration
- High tissue penetration ensures effective drug concentration at the site of infection
- Once-daily dosing improves compliance and reduces treatment burden
- Proven efficacy in polymicrobial and resistant infections minimizes treatment failure
- Well-established safety profile with extensive clinical use and post-marketing surveillance
- Available in multiple strengths for tailored dosing based on infection severity and renal function
Common use
Lquin is commonly prescribed for community-acquired pneumonia, acute bacterial sinusitis, acute bacterial exacerbation of chronic bronchitis, complicated and uncomplicated urinary tract infections, acute pyelonephritis, and skin and skin structure infections. It is also used in the treatment of inhalational anthrax (post-exposure) and plague. Its use is generally reserved for cases where first-line agents are inappropriate due to resistance, allergy, or clinical severity.
Dosage and direction
The recommended dosage varies by infection type and severity. For most infections, the typical dose is 250mg to 750mg orally once every 24 hours. Treatment duration usually ranges from 7 to 14 days, though some infections may require longer therapy. Tablets should be swallowed whole with a full glass of water, and may be taken with or without food. Patients should be advised to complete the entire course of therapy even if symptoms improve, to prevent resistance development. Dosage must be adjusted in patients with renal impairment (CrCl <50 mL/min).
Precautions
Patients should be advised to maintain adequate hydration to prevent crystal formation. Use with caution in patients with known or suspected central nervous system disorders, as fluoroquinolones may lower seizure threshold. Avoid excessive sunlight or UV exposure due to photosensitivity risk. Monitor for signs of tendon inflammation or rupture, particularly in elderly patients, those taking corticosteroids, or those with renal impairment. Blood glucose should be monitored in diabetic patients, as dysglycemia has been reported.
Contraindications
Lquin is contraindicated in patients with a history of hypersensitivity to levofloxacin, other quinolones, or any component of the formulation. It should not be used in patients with a history of tendon disorders related to fluoroquinolone use. Concomitant administration with tizanidine is contraindicated.
Possible side effect
Common adverse reactions (≥1%) include nausea, diarrhea, headache, insomnia, constipation, and dizziness. Less frequently, patients may experience photosensitivity, tendonitis, peripheral neuropathy, QT prolongation, hepatic enzyme elevation, or Clostridioides difficile-associated diarrhea. Serious but rare side effects include tendon rupture, severe hypersensitivity reactions, central nervous system effects (seizures, psychosis), and blood dyscrasias.
Drug interaction
Lquin may interact with multivalent cation-containing products (antacids, sucralfate, metal cations), which significantly reduce absorption—administer at least 2 hours before or 2 hours after Lquin. It may enhance the effects of warfarin (monitor INR closely). Concomitant use with drugs that prolong QT interval (antiarrhythmics, antipsychotics, macrolides) should be avoided. Nonsteroidal anti-inflammatory drugs may increase CNS stimulation risk. Levofloxacin may affect blood glucose levels when used with antidiabetic agents.
Missed dose
If a dose is missed, it should be taken as soon as remembered unless it is nearly time for the next dose. In that case, skip the missed dose and resume the regular dosing schedule. Do not double the dose to make up for a missed one.
Overdose
Symptoms of overdose may include dizziness, tremor, nausea, vomiting, and seizures. Management is supportive; ECG monitoring is advised due to potential QT prolongation. Hemodialysis removes approximately 10% of the administered dose and may be considered in severe cases.
Storage
Store at room temperature (20–25°C or 68–77°F), in a tightly closed container, protected from light and moisture. Keep out of reach of children and pets. Do not use after the expiration date printed on the packaging.
Disclaimer
This information is intended for healthcare professionals and should not replace professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider for personalized recommendations. The prescriber should review the full prescribing information before initiating therapy.
Reviews
“Lquin has been a reliable option in our hospital for managing resistant Pseudomonas infections. The once-daily dosing is particularly advantageous for outpatient parenteral therapy programs.” – Infectious Disease Specialist, 12 years experience
“In cases of complicated UTIs with ESBL-producing organisms, Lquin has demonstrated consistent efficacy. I appreciate the flexibility in dosing for renal adjustment.” – Nephrologist, 8 years experience
“While effective, I reserve Lquin for cases where alternatives are not suitable due to the black box warnings. Patient education on tendon and neuropsychiatric risks is crucial.” – Internal Medicine Physician, 15 years experience